Author: Kaye

Kaye

Kaye obtained her Masters of Pharmacy degree from the University College London and has spent the better part of her career as a clinical pharmacist in a tertiary care hospital. Her professional interests are centred on HEOR and HTA work, in hopes of ultimately influencing cost-effective decisions for patient care.

FDA Approves Xenoview for Use with MRI for the Evaluation of Lung Ventilation

By KayeJanuary 27, 20230

In Dec 2022, Xenoview™, a hyperpolarized contrast agent prepared from a proprietary Xenon 129Xe Gas Blend, received FDA approval

FDA Approves Ublituximab for Relapsing Forms of Multiple Sclerosis

By KayeJanuary 20, 20230

In Dec 2022, the FDA approved BRIUMVI™, a chimeric monoclonal antibody (mAb) labelled for the treatment of RMS

FDA approves lenacapavir (Sunleca®) in heavily pre-treated adults with multi-drug resistant HIV-1 infection

By KayeJanuary 13, 20230

Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022

A New Paradigm in Severe Burn Treatment – FDA Approves Anacaulase (NexoBrid®)

By KayeJanuary 3, 20230

In Dec 2022, the US Food and Drug Administration (FDA) approved MediWound’s biologic license application (BLA) for anacaulase-bcdb (NexoBrid®)

Terlivaz (Terlipressin) to Improve Kidney Function in Adults with Hepatorenal Syndrome

By KayeNovember 17, 20220

Gadopiclenol (Elucirem™) for Contrast-Enhanced MRI

By KayeOctober 20, 20220

The US FDA granted regulatory approval to Gadopiclenol (Elucirem™), a new macrocyclic GBCA for use in adults and children aged 2 years and older, for contrast-enhanced MRI.

Omlonti (Omidenepag Isopropyl) for the Reduction of Elevated Intraocular Pressure

By KayeOctober 6, 20220

On 22 Sep 2022, the US FDA approved Omlonti® 0.002% eye drops for the reduction of elevated intraocular pressure. Read more

Risdiplam: Spinal Muscular Atrophy (SMA) Treatment

By KayeSeptember 12, 20220

Risdiplam is the only disease-modifying therapy granted local market authorisation by HSA. Read about how it is used as a treatment for SMA

HSA approves Belimumab (Benlysta) for Lupus Nephritis

By KayeSeptember 3, 20220

Belimumab is a fully human IgG1λ recombinant monoclonal antibody directed against B lymphocyte stimulator. Know more about its drug profile

Pralsetinib: Targeted Therapies for RET-Fusion Positive NSCLC

By KayeAugust 25, 20220

Pralsetinib is a RET receptor tyrosine kinase inhibitor used to treat metastatic RET-driven non-small cell lung cancer. Learn more

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

What's Hot

5 Strategies for Doctors to Attract More Patients

The Placebo Effect of Vitamins: Belief vs Reality

Does Freezing Bread Really Lower Its Glycaemic Index?

Author: Kaye

FDA Approves Xenoview for Use with MRI for the Evaluation of Lung Ventilation

FDA Approves Ublituximab for Relapsing Forms of Multiple Sclerosis

FDA approves lenacapavir (Sunleca®) in heavily pre-treated adults with multi-drug resistant HIV-1 infection

A New Paradigm in Severe Burn Treatment – FDA Approves Anacaulase (NexoBrid®)

Terlivaz (Terlipressin) to Improve Kidney Function in Adults with Hepatorenal Syndrome

Gadopiclenol (Elucirem™) for Contrast-Enhanced MRI

Omlonti (Omidenepag Isopropyl) for the Reduction of Elevated Intraocular Pressure

Risdiplam: Spinal Muscular Atrophy (SMA) Treatment

HSA approves Belimumab (Benlysta) for Lupus Nephritis

Pralsetinib: Targeted Therapies for RET-Fusion Positive NSCLC

5 Strategies for Doctors to Attract More Patients

The Placebo Effect of Vitamins: Belief vs Reality

Does Freezing Bread Really Lower Its Glycaemic Index?

How Telemedicine is Transforming The Way Singaporeans Manage Diabetes

Subscribe to Updates

What's Hot

Author: Kaye

Subscribe to Updates